[Skip to Content]
[Skip to Content Landing]
Views 90
Citations 0
Comment & Response
June 2018

Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer

Author Affiliations
  • 1Département d’Oncologie Médicale, Institut du Cancer de Montpellier, Montpellier, France
  • 2University Cancer Center Leipzig, University Hospital Leipzig, Leipzig, Germany
JAMA Oncol. 2018;4(6):887-888. doi:10.1001/jamaoncol.2018.0239

To the Editor In a recent issue of JAMA Oncology, Suntharalingam et al1 reported that the addition of cetuximab to concurrent chemoradiation therapy (CRT) with paclitaxel and cisplatin failed to improve the survival of patients undergoing nonoperative treatment of esophageal cancer. They concluded that RTOG 0436 had negative results and suggested focusing future trials on patients with actionable molecular targets. Surprisingly, Suntharalingam et al1 also stated that because of the toxic effects observed in both experimental and control treatment arms, they were inclined to recommend a systemic therapy that uses a platinum-taxane combination rather than fluorouracil.